FDA Considering Compounding Pharmacy Regulations

In a statement to Drug Topics, the International Academy of Compounding Pharmacists (IACP) said that the FDA was overstepping Congress's intent.According to the IACP, statements made during the passage of the bill "made clear that officeuse compounding was to be left to state law and that...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2017-10, Vol.161 (10), p.14-15
Main Author: Hamm, Nicholas
Format: Magazinearticle
Language:English
Subjects:
Cadden, Barry
Drug stores
Laws, regulations and rules
Pharmacists
Pharmacy
Regulated industries
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a statement to Drug Topics, the International Academy of Compounding Pharmacists (IACP) said that the FDA was overstepping Congress's intent.According to the IACP, statements made during the passage of the bill "made clear that officeuse compounding was to be left to state law and that the memorandum of understanding found within section 503A was not to include dispensing."According to IACP, "H.R. 2871 will help clarify the DQSA in a way that will better align the statute with congressional intent.
ISSN:0012-6616
1937-8157